Home »

La Jolla Pharmaceutical Company Receives Orphan Designation From FDA

SAN DIEGO, CA — (Marketwired) — 07/17/13 — (OTCBB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics targeting , announced today that the FDA Office of Orphan Products Development has granted an "Orphan Drug" designation to La Jolla-s drug candidate LJPC-0712 for treatment of Niemann-Pick type C disease."Having received a second orphan designation from FDA, our team continues to build La Jolla into a leader in the development of


© 2021 88Finance. All Rights Reserved. Log in

- Copyright by LayerMedia

Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de